AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18095278 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fatigue
Number of subjects: 0
Study 16682260 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 1026
Study 16682260 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 1026
Study 12952417 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic produced diet (OPD)
Number of subjects: 16
Study 12952417 — intervention group
Group type: COMPARATOR
Intervention: Conventional produced diet (CPD)
Number of subjects: 16
Study 11029974 — intervention group
Group type: EXPERIMENTAL
Intervention: D-tagatose
Number of subjects: 19
Study 11029974 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 19
Study 8857138 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbo cup forceps (3.3 mm diameter) with CLOtest
Number of subjects: 102
Study 8857138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiny cup forceps (1.8 mm diameter) with hpfast
Number of subjects: 102
Study 8857138 — intervention group
Group type: COMPARATOR
Intervention: Combination of any forceps with CLOtest or hpfast
Number of subjects: 102
Study 1355640 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta‐2‐agonist (salbutamol 0.2 mg) plus inhaled corticosteroid (budesonide 0.2 mg) three times a day (BA+CS)
Number of subjects: 116
Study 1355640 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beta‐2‐agonist (salbutamol 0.2 mg) plus placebo three times a day (BA+PL)
Number of subjects: 116
Study 1355640 — intervention group
Group type: EXPERIMENTAL
Intervention: BA+CS
Number of subjects: 116
Study 1355640 — intervention group
Group type: COMPARATOR
Intervention: BA+PL
Number of subjects: 116
Study 31302012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 70% (IF70)
Number of subjects: 76
Study 31302012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 100% (IF100)
Number of subjects: 76
Study 31302012 — intervention group
Group type: COMPARATOR
Intervention: Daily calorie restriction 70% (DR70)
Number of subjects: 76
Study 27414470 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT) delivered by lay counselors
Number of subjects: 12
Study 26331348 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 mg/kg subcutaneously) in combination with G-CSF (5 mg/kg/day increasing to 10 mg/kg/day)
Number of subjects: 45
Study 26331348 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone (without plerixafor)
Number of subjects: 45
Study 26331348 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (240 mg/kg)
Number of subjects: 45
Study 26331348 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor and G-CSF
Number of subjects: 45
Study 24165214 — intervention group
Group type: EXPERIMENTAL
Intervention: Event History Calendar (EHC)
Number of subjects: 186
Study 24165214 — intervention group
Group type: COMPARATOR
Intervention: Guidelines for Adolescent Preventive Services (GAPS)
Number of subjects: 186
Study 20817283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) abciximab administration
Number of subjects: 154
Study 20817283 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous (IV) abciximab administration
Number of subjects: 154
Study 19363853 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB + LCD therapy
Number of subjects: 0
Study 19363853 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB alone
Number of subjects: 0
Study 16429087 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 52
Study 16429087 — intervention group
Group type: COMPARATOR
Intervention: No stimulant medication (comparison group)
Number of subjects: 52
Study 15238567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (16 mg once daily)
Number of subjects: 809
Study 15238567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 11710664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance training (70-90% 1RM)
Number of subjects: 30
Study 11710664 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance training (40-60% 1RM)
Number of subjects: 30
Study 9681307 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral midazolam
Number of subjects: 50
Study 9681307 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg oral midazolam
Number of subjects: 50
Study 8023667 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative infiltration of the surgical area with bupivacaine 0.25%, 40 ml (group I)
Number of subjects: 49
Study 8023667 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (group II)
Number of subjects: 49
Study 2641954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NaF solution
Number of subjects: 295
Study 2641954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 4460068 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 ounces (360 ml) of 95 proof ethanol (133.68 g ethanol)
Number of subjects: 5
Study 4460068 — intervention group
Group type: COMPARATOR
Intervention: Non availability of ethanol
Number of subjects: 5
Study 31486196 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantain syrup and placebo capsule
Number of subjects: 68
Study 31486196 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid capsule and placebo syrup
Number of subjects: 68
Study 31562509 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel meal detection algorithm using CGM data
Number of subjects: 30
Study 31562509 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world data analysis of meal detection
Number of subjects: 30
Study 28483402 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for 7 days, 200 mg on the first day)
Number of subjects: 305
Study 28483402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 28483402 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 305
Study 26272281 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 at 200 μg/d
Number of subjects: 159
Study 26272281 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 at 400 μg/d
Number of subjects: 159
Study 26272281 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 at 800 μg/d
Number of subjects: 159
Study 26272281 — intervention group
Group type: EXPERIMENTAL
Intervention: S0597 (all doses)
Number of subjects: 159
Study 26272281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 23736782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraset rest intervals (ISR)
Number of subjects: 22
Study 23736782 — intervention group
Group type: COMPARATOR
Intervention: Traditional rest (TRD)
Number of subjects: 22
Study 21658839 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight HPS 120-W laser PVP
Number of subjects: 50
Study 21658839 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 50
Study 17935216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress disorder (ASD) participants
Number of subjects: 25
Study 17935216 — intervention group
Group type: COMPARATOR
Intervention: Non‐traumatized controls
Number of subjects: 25
Study 16434506 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL‐ST (Sirolimus therapy after CsA withdrawal)
Number of subjects: 430
Study 16434506 — intervention group
Group type: COMPARATOR
Intervention: SRL‐CsA‐ST (Sirolimus with Cyclosporine and steroids)
Number of subjects: 430
Study 12091818 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive coronary artery bypass grafting (surgical intervention)
Number of subjects: 102
Study 12091818 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty with primary stenting (stenting)
Number of subjects: 102
Study 12091818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 102
Study 10048612 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of triple dye
Number of subjects: 180
Study 10048612 — intervention group
Group type: COMPARATOR
Intervention: Multiple applications of triple dye
Number of subjects: 180
Study 7734350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy for AML with a monoblastic component
Number of subjects: 86
Study 2073671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg nightly (n = 17)
Number of subjects: 67
Study 2073671 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (n = 8)
Number of subjects: 67
Study 2073671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly (n = 23)
Number of subjects: 67
Study 2073671 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg b.i.d. (n = 19)
Number of subjects: 67
Study 2073671 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 67
Study 2073671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 67
Study 6105721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 100
Study 6105721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6333649 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone sodium succinate (30 mg/kg q6h X2, then 250 mg q6h X6, then tapering over 8 days)
Number of subjects: 88
Study 6333649 — intervention group
Group type: COMPARATOR
Intervention: Low dose methylprednisolone (1.5 mg/kg q6h X2, then 25 mg q6h X6, then tapering over 8 days)
Number of subjects: 88
Study 6333649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 6333649 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone sodium succinate
Number of subjects: 88
Study 6333649 — intervention group
Group type: COMPARATOR
Intervention: Low dose methylprednisolone and placebo
Number of subjects: 88
Study 31132584 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 12
Study 31132584 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 12
Study 28840969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic botulinum toxin type A injection (200-300 UI in 6-8 mL saline)
Number of subjects: 20
Study 28840969 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (SS)
Number of subjects: 20
Study 27661432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (ILTA) with carbon dioxide laser
Number of subjects: 60
Study 27661432 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (ILTA) with cryotherapy
Number of subjects: 60
Study 24726027 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET) for 12 sessions
Number of subjects: 34
Study 24726027 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 34
Study 24726027 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 34
Study 22329608 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/9 μg bid
Number of subjects: 1028
Study 22329608 — intervention group
Group type: COMPARATOR
Intervention: BUD pMDI 160 μg bid
Number of subjects: 1028
Study 22329608 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 320/9 μg bid
Number of subjects: 1028
Study 22329608 — intervention group
Group type: COMPARATOR
Intervention: BUD pMDI 320 μg bid
Number of subjects: 1028
Study 22329608 — intervention group
Group type: COMPARATOR
Intervention: BUD dry powder inhaler 360 μg bid
Number of subjects: 1028
Study 19841982 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate microsurgical free flap reconstruction
Number of subjects: 773
Study 19841982 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate microsurgical free flap reconstruction (randomized matched-pair analysis)
Number of subjects: 773
Study 19841982 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of tumor (T3 and T4)
Number of subjects: 773
Study 19841982 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of tumor (T1 and T2)
Number of subjects: 773
Study 17644330 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and tamoxifen 30 mg/day for one year (RT+tam)
Number of subjects: 724
Study 17644330 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (tam)
Number of subjects: 724
Study 17644330 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy 50 Gy/25 fractions to chest wall and regional lymph nodes (RT)
Number of subjects: 724
Study 16096179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% applied four times daily (QID)
Number of subjects: 49
Study 16096179 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream 1% applied twice daily (BID)
Number of subjects: 49
Study 11792138 — intervention group
Group type: EXPERIMENTAL
Intervention: First day angiography/angioplasty
Number of subjects: 131
Study 11792138 — intervention group
Group type: COMPARATOR
Intervention: Early conservative therapy
Number of subjects: 131
Study 10521814 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal urine beta-core human chorionic gonadotrophin (hCG) screening
Number of subjects: 6730
Study 7738628 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg
Number of subjects: 987
Study 7738628 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 987
Study 7738628 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 0.15 mg/kg
Number of subjects: 987
Study 2187948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 687
Study 2187948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 7031085 — intervention group
Group type: EXPERIMENTAL
Intervention: Triton X-100 SPV
Number of subjects: 76
Study 7031085 — intervention group
Group type: COMPARATOR
Intervention: Tween-ether SPV
Number of subjects: 76
Study 30243839 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 0
Study 30243839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30217943 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) inhalation
Number of subjects: 60
Study 30217943 — intervention group
Group type: COMPARATOR
Intervention: Sterilized water (control)
Number of subjects: 60
Study 26762125 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of community groups with high-rated facilitators (n=27)
Number of subjects: 1508
Study 26762125 — intervention group
Group type: COMPARATOR
Intervention: Control communes (n=46)
Number of subjects: 1508
Study 24566755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal fibronectin (FFN)
Number of subjects: 214
Study 24566755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length ≤ 25 mm
Number of subjects: 214
Study 24566755 — intervention group
Group type: COMPARATOR
Intervention: 17-hydroxyprogesterone caproate (17OHPc)
Number of subjects: 214
Study 22894939 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HMOs above the median (1.87 g/L)
Number of subjects: 203
Study 22894939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose concentrations
Number of subjects: 203
Study 22894939 — intervention group
Group type: COMPARATOR
Intervention: 3'-sialyllactose (3'-SL) per total HMOs
Number of subjects: 203
Study 22894939 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-3'-SL HMOs
Number of subjects: 203
Study 20655106 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (5 parts per million)
Number of subjects: 800
Study 20655106 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas (nitrogen gas)
Number of subjects: 800
Study 17559369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS), 3 sachets daily for 8 weeks
Number of subjects: 104
Study 17559369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 17559369 — intervention group
Group type: COMPARATOR
Intervention: Dioctahedral smectite (DS) and Placebo
Number of subjects: 104
Study 16236851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity cycle ergometer exercise training program for 45 min, three times a week for 7 weeks
Number of subjects: 24
Study 16236851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity cycle ergometer exercise training
Number of subjects: 24
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunting
Number of subjects: 0
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 0
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative EEG monitoring
Number of subjects: 0
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of anaesthetic
Number of subjects: 0
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative anticoagulation (not used)
Number of subjects: 0
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time <1 h or >1.5 h
Number of subjects: 0
Study 11863328 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons' subjective assessment of operation difficulty
Number of subjects: 0
Study 10612566 — intervention group
Group type: COMPARATOR
Intervention: Vbeta2 gene expression in BALF
Number of subjects: 17
Study 10612566 — intervention group
Group type: COMPARATOR
Intervention: Vbeta6 gene expression in BALF
Number of subjects: 17
Study 10612566 — intervention group
Group type: COMPARATOR
Intervention: Vbeta2 gene overexpression in BALF samples
Number of subjects: 17
Study 10612566 — intervention group
Group type: COMPARATOR
Intervention: Vbeta6 gene overexpression in BALF samples
Number of subjects: 17
Study 7717715 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 40
Study 7717715 — intervention group
Group type: COMPARATOR
Intervention: Non-granisetron
Number of subjects: 40
Study 1674963 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 60
Study 1674963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipecacuanha-induced emesis
Number of subjects: 60
Study 1674963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 6800003 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 40
Study 6800003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam
Number of subjects: 40
Study 6800003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31957527 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) combined with prednisone
Number of subjects: 60
Study 31957527 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) combined with prednisone
Number of subjects: 60
Study 30518130 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplement (0.4 g protein/kg/day)
Number of subjects: 29
Study 30518130 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 29
Study 26286012 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles injected beneath the lesion sites 3 cm
Number of subjects: 24
Study 26286012 — intervention group
Group type: COMPARATOR
Intervention: No treatment with carbon nanoparticles (Control Group B)
Number of subjects: 24
Study 25617572 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming platform (Wii-Fit)
Number of subjects: 42
Study 25617572 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 42
Study 23286611 — intervention group
Group type: EXPERIMENTAL
Intervention: Management informatics system intervention for mammography screening
Number of subjects: 32688
Study 21085810 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) rinsing for 21 days
Number of subjects: 20
Study 21085810 — intervention group
Group type: COMPARATOR
Intervention: Control group (plaque-free surfaces)
Number of subjects: 20
Study 17628971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 120
Study 17628971 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 120
Study 16327031 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (400 mg alpha‐lipoic acid, 200 mg co‐enzyme Q10, 12 mg manganese, 600 mg vitamin C, 800 mg N‐acetyl cysteine, 400 microg selenium, and 400 IU alpha‐tocopherol per day)
Number of subjects: 14
Study 16327031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11998383 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluothane
Number of subjects: 40
Study 11998383 — intervention group
Group type: COMPARATOR
Intervention: No treatment with perfluothane (Control)
Number of subjects: 40
Study 9714109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 19
Study 9714109 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 19
Study 9714109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking with nitroprusside
Number of subjects: 19
Study 7985708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (20 g/day) administered twice a day for 36 weeks
Number of subjects: 59
Study 2519943 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) 12 mmol
Number of subjects: 20
Study 2519943 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium-aspartate (KMA) 12 mmol
Number of subjects: 20
Study 30106535 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg codeine + 500 mg paracetamol (CP)
Number of subjects: 60
Study 30106535 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen (IB)
Number of subjects: 60
Study 30106535 — intervention group
Group type: COMPARATOR
Intervention: 400 mg placebo (PL)
Number of subjects: 60
Study 30106535 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide bleaching
Number of subjects: 60
Study 27799178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg perineurally with ropivacaine 0.5%
Number of subjects: 20
Study 27799178 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% alone (saline control)
Number of subjects: 20
Study 27799178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg perineurally
Number of subjects: 20